Management of Varicella Disease Progression

Risk Stratification and Treatment Approach

The Centers for Disease Control and Prevention recommends that for immunocompromised patients with varicella, intravenous acyclovir should be initiated within 24 hours of rash onset to reduce morbidity and mortality, while for otherwise healthy adults and adolescents, oral acyclovir should be considered if started within 24 hours 1, 2
The American Academy of Pediatrics and the Advisory Committee on Immunization Practices identify immunocompromised patients as requiring intravenous acyclovir immediately when varicella is diagnosed, as this population faces significant risk of dissemination and death without prompt antiviral therapy 1, 2
Pregnant women with serious viral-mediated complications, such as pneumonia, should receive intravenous acyclovir 3

The American College of Obstetricians and Gynecologists notes that acyclovir is classified as FDA Category B in pregnancy, with reassuring safety data from exposures showing no increased birth defect rates compared to the general population 3
The American Academy of Pediatrics supports the use of oral acyclovir for pregnant women with increased risk for moderate-to-severe disease 3

The Centers for Disease Control and Prevention recommends that oral acyclovir should be considered for otherwise healthy persons at increased risk for moderate to severe varicella, but only if initiated within 24 hours of rash onset 1, 3
The Advisory Committee on Immunization Practices and the American Academy of Pediatrics identify specific populations where oral therapy may be beneficial, including persons aged ≥13 years, children with chronic cutaneous or pulmonary disorders, and persons receiving long-term salicylate therapy 1, 3

The Centers for Disease Control and Prevention notes that acyclovir loses efficacy when initiated >24 hours after rash onset in most populations 1
The American Academy of Pediatrics recommends that acyclovir is not indicated for prophylactic use in otherwise healthy individuals after varicella exposure—vaccination is the method of choice 3

The Centers for Disease Control and Prevention recommends supportive care alone for otherwise healthy children with varicella, while oral acyclovir should be initiated within 24 hours of rash onset for persons ≥13 years, immunocompromised patients, pregnant women with complications, and children with chronic cutaneous or pulmonary disorders 4, 5

For immunocompetent children (<13 years), the American Academy of Pediatrics recommends supportive care only for otherwise healthy children 4
The Centers for Disease Control and Prevention suggests oral acyclovir for children with chronic cutaneous disorders, such as eczema 6
For adolescents and adults (≥13 years), the Centers for Disease Control and Prevention recommends oral acyclovir 800 mg four times daily for 5 days if initiated within 24 hours of rash onset 4
The Infectious Diseases Society of America recommends intravenous acyclovir 10 mg/kg every 8 hours for 7-10 days for immunocompromised patients 5

The Centers for Disease Control and Prevention recommends varicella vaccine within 3 days of exposure for susceptible individuals without contraindications, which is >90% effective in preventing disease 7, 8
For high-risk individuals with contraindications to vaccination, the American College of Obstetricians and Gynecologists recommends varicella-zoster immune globulin within 96 hours of exposure 7, 8

The Centers for Disease Control and Prevention recommends isolating patients until all lesions are crusted, typically 5-7 days after rash onset 9, 6
The Society for Healthcare Epidemiology of America recommends airborne and contact precautions in healthcare settings 10, 11

New lesion formation typically continues for 3-5 days in immunocompetent individuals, according to the Centers for Disease Control and Prevention (CDC) 12
Adults face significantly higher complication rates than children, with case-fatality rates 21.3 per 100,000 cases in adults versus 0.8 per 100,000 in children aged 1-4 years, as reported by the CDC 12

High-risk groups, including HIV-infected patients, transplant recipients, cancer patients on chemotherapy, and those receiving high-dose corticosteroids, require immediate initiation of intravenous acyclovir upon diagnosis, ideally within 24 hours of rash onset, as recommended by the American Academy of Pediatrics 13

Varicella vaccine administered within 3 days (up to 5 days) of exposure is >90% effective at preventing disease in susceptible immunocompetent individuals, according to the CDC 14
VariZIG should be administered within 96 hours (extended to 10 days per 2013 CDC guidelines) for high-risk individuals who cannot receive vaccine, including immunocompromised patients, pregnant women without evidence of immunity, and newborns whose mothers developed varicella from 5 days before to 2 days after delivery, as recommended by the CDC 15, 16
VariZIG dosing is 125 IU/10 kg body weight intramuscularly, maximum 625 IU (five vials); minimum dose 62.5 IU for infants ≤2.0 kg, as specified by the CDC 15, 16

If varicella develops despite VariZIG, antiviral therapy should be instituted immediately, as recommended by the CDC 15, 16
The CDC recommends that newborns whose mothers developed varicella from 5 days before to 2 days after delivery should not be discharged without VariZIG, due to the high mortality risk in this population 15, 16